 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...6162636465666768697071...7475» |
- ||||| Fovista (pegpleranib) / Roche, Astellas
New P2 trial, Combination therapy: A 24 Month Phase 2a Open Label, Randomized Study of Avastin (clinicaltrials.gov) - Mar 14, 2015
P2, N=60, Recruiting, Sponsor: Ophthotech Corporation
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Monotherapy: WAVE: Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion (clinicaltrials.gov) - Mar 14, 2015
P4, N=30, Active, not recruiting, Sponsor: Charles C Wykoff, PhD, MD
Recruiting --> Active, not recruiting
- || Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Trial primary completion date, Combination therapy, Monotherapy: EVEREST II: Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) (clinicaltrials.gov) - Mar 11, 2015
P4, N=320, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2016 --> Apr 2017
- | Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date, Trial primary completion date: TIDE AMD: Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Mar 11, 2015
P4, N=40, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2016 --> Apr 2017 Initiation date: Oct 2014 --> Mar 2015 | Trial primary completion date: Oct 2014 --> May 2016
- | Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date, Trial primary completion date: Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (clinicaltrials.gov) - Mar 11, 2015
P4, N=40, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Oct 2014 --> Mar 2015 | Trial primary completion date: Oct 2014 --> May 2016 Initiation date: Nov 2014 --> Mar 2015 | Trial primary completion date: Nov 2014 --> May 2016
- acrizanib (LHA510) / Novartis
Enrollment open: LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration (clinicaltrials.gov) - Mar 7, 2015
P2, N=60, Recruiting, Sponsor: Alcon, a Novartis Company
Initiation date: Nov 2014 --> Mar 2015 | Trial primary completion date: Nov 2014 --> May 2016 Not yet recruiting --> Recruiting
- PF582 (ranibizumab biosimilar) / Ligand
Trial primary completion date: Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration (clinicaltrials.gov) - Mar 3, 2015
P1/2, N=24, Active, not recruiting, Sponsor: Pfenex, Inc
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2014 --> Dec 2015
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity (clinicaltrials.gov) - Mar 3, 2015
P3, N=300, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | Lucentis (ranibizumab) / Roche, Novartis
Phase classification, Combination therapy: Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME) (clinicaltrials.gov) - Feb 28, 2015
P2, N=90, Not yet recruiting, Sponsor: Starr Muscle
Trial primary completion date: Dec 2014 --> Dec 2015 Phase classification: P3 --> P2
- Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion (clinicaltrials.gov) - Feb 20, 2015
P=N/A, N=30, Recruiting, Sponsor: Brian Burke, MPH
Phase classification: P3 --> P2 Trial primary completion date: Dec 2014 --> Jun 2015
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron
Trial initiation date: TITAN: Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=200, Not yet recruiting, Sponsor: Bayer
Trial primary completion date: Dec 2014 --> Jun 2015 Initiation date: Jan 2015 --> Jun 2015
- ||| Stivarga (regorafenib) / Bayer
Enrollment change: DREAM: Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration (clinicaltrials.gov) - Feb 19, 2015
P2a, N=350, Recruiting, Sponsor: Bayer
Initiation date: Jan 2015 --> Jun 2015 N=540 --> 350
- ||||| Lucentis (ranibizumab) / Roche, Novartis
New P4 trial, Head-to-Head: DIVERSE: Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema (clinicaltrials.gov) - Feb 19, 2015
P4, N=300, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME (clinicaltrials.gov) - Feb 18, 2015
P2, N=100, Active, not recruiting, Sponsor: Arshad Khanani
- ||| Beovu (brolucizumab-dbll) / Novartis
Enrollment change: ESBA1008 Microvolume Study (clinicaltrials.gov) - Feb 12, 2015
P2, N=107, Completed, Sponsor: Alcon Research
N=540 --> 350 N=52 --> 107
- Lucentis (ranibizumab) / Roche, Novartis
Phase classification: SEAGUL: Study Evaluating Genotypes Using Lucentis (clinicaltrials.gov) - Feb 11, 2015
P=N/A, N=65, Terminated, Sponsor: University of Utah
N=52 --> 107 Phase classification: P4 --> P=N/A
- | hI-con1 (ICON-1) / Endpoint Health
New P2 trial: EMERGE: Study Evaluating Intravitreal hI-con1 (clinicaltrials.gov) - Feb 9, 2015
P2, N=90, Recruiting, Sponsor: Iconic Therapeutics, Inc.
- ||||| Avegra (bevacizumab biosimilar) / Biocad
Trial initiation date, Trial primary completion date: GALATIR: Safety and Efficacy Study of BCD-021 Compared to Lucentis (clinicaltrials.gov) - Feb 6, 2015
P3, N=108, Not yet recruiting, Sponsor: Biocad
Phase classification: P4 --> P=N/A Initiation date: Mar 2014 --> Dec 2015 | Trial primary completion date: Mar 2016 --> Dec 2016
- || Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: POLARIS: Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=807, Recruiting, Sponsor: Bayer
Initiation date: Mar 2014 --> Dec 2015 | Trial primary completion date: Mar 2016 --> Dec 2016 Trial primary completion date: Jan 2015 --> Apr 2015
- | acrizanib (LHA510) / Novartis
New P2 trial: LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration (clinicaltrials.gov) - Feb 5, 2015
P2, N=60, Not yet recruiting, Sponsor: Alcon, a Novartis Company
- ASP8232 / Astellas
Enrollment open: A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) (clinicaltrials.gov) - Feb 2, 2015
P2, N=84, Recruiting, Sponsor: Astellas Pharma Europe B.V.
Trial primary completion date: Jan 2015 --> Apr 2015 Not yet recruiting --> Recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Trial primary completion date, Monotherapy: PROTEUS: Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy. (clinicaltrials.gov) - Jan 30, 2015
P2/3, N=94, Recruiting, Sponsor: Association for Innovation and Biomedical Research on Light and Image
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2015 --> Mar 2016
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
New P2 trial, New P3 trial, Combination therapy: Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME) (clinicaltrials.gov) - Jan 29, 2015
P3, N=90, Not yet recruiting, Sponsor: Starr Muscle
- |||| Beovu (brolucizumab-dbll) / Novartis
Trial completion: ESBA1008 Microvolume Study (clinicaltrials.gov) - Jan 29, 2015
P2, N=52, Completed, Sponsor: Alcon Research
Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2015 --> Mar 2016 Active, not recruiting --> Completed
- ||||| Fumena (vorolanib) / Tyrogenex
New P2 trial, Monotherapy, Head-to-Head: X-82 to Treat Age-related Macular Degeneration (clinicaltrials.gov) - Jan 28, 2015
P2, N=132, Not yet recruiting, Sponsor: Xcovery Vision, LLC
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Trial initiation date, Monotherapy: Stereotactic Radiotherapy for Wet AMD (STAR) (clinicaltrials.gov) - Jan 28, 2015
P3, N=411, Recruiting, Sponsor: King's College Hospital NHS Trust
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Dec 2014
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage: (clinicaltrials.gov) - Jan 28, 2015
P2/3, N=24, Active, not recruiting, Sponsor: King's College Hospital NHS Trust
Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Dec 2014 Recruiting --> Active, not recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion (clinicaltrials.gov) - Jan 26, 2015
P=N/A, N=30, Completed, Sponsor: Yonsei University
Recruiting --> Active, not recruiting Recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema (clinicaltrials.gov) - Jan 22, 2015
P1/2, N=150, Active, not recruiting, Sponsor: Palmetto Retina Center, LLC
Recruiting --> Completed Recruiting --> Active, not recruiting
- Lucentis (ranibizumab) / Roche, Novartis
New P2/3 trial: Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study (clinicaltrials.gov) - Jan 20, 2015
P2/3, N=36, Completed, Sponsor: University of Science Malaysia
- | Rayoqta (abicipar pegol) / Molecular Partners
Enrollment closed, Trial primary completion date: A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Jan 18, 2015
P2, N=25, Active, not recruiting, Sponsor: Allergan
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Mar 2015
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron
Trial primary completion date: TITAN: Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD (clinicaltrials.gov) - Jan 17, 2015
P=N/A, N=200, Not yet recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Mar 2015 Trial primary completion date: Jun 2016 --> Dec 2016
- ||| Rayoqta (abicipar pegol) / Molecular Partners
Enrollment closed, Trial primary completion date: A Study of Abicipar Pegol in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Jan 17, 2015
P2, N=151, Active, not recruiting, Sponsor: Allergan
Trial primary completion date: Jun 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2015 --> Apr 2015
- |||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial primary completion date: LUCAS (Lucentis Compared to Avastin Study) (clinicaltrials.gov) - Jan 17, 2015
P4, N=420, Completed, Sponsor: Oslo University Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2015 --> Apr 2015 Active, not recruiting --> Completed | Trial primary completion date: Jul 2013 --> Aug 2014
- || LKA651 / Novartis, MorphoSys
Trial primary completion date: A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Jan 15, 2015
P1, N=72, Not yet recruiting, Sponsor: Alcon Research
Active, not recruiting --> Completed | Trial primary completion date: Jul 2013 --> Aug 2014 Trial primary completion date: Sep 2016 --> Dec 2016
- PAN-90806 / PanOptica
Trial primary completion date: Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD (clinicaltrials.gov) - Jan 15, 2015
P1, N=50, Recruiting, Sponsor: PanOptica, Inc.
Trial primary completion date: Sep 2016 --> Dec 2016 Trial primary completion date: Nov 2014 --> Sep 2015
- |||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Head-to-Head: SALUTE-D: Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME (clinicaltrials.gov) - Jan 15, 2015
P3, N=104, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2014 --> Sep 2015 Not yet recruiting --> Recruiting
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO (clinicaltrials.gov) - Jan 15, 2015
P4, N=175, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD (clinicaltrials.gov) - Jan 8, 2015
P3, N=644, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Initiation date: Dec 2013 --> Oct 2004
- ||| iSONEP (sonepcizumab) / Pfizer, Apollo Endosurgery
Enrollment closed, Trial primary completion date, Monotherapy: Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD (clinicaltrials.gov) - Jan 7, 2015
P2, N=160, Active, not recruiting, Sponsor: Lpath, Inc.
Initiation date: Dec 2013 --> Oct 2004 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Jun 2015
- Lucentis (ranibizumab) / Roche, Novartis
Clinical: Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration (clinicaltrials.gov) - Jan 2, 2015
P=N/A, N=50, Recruiting, Sponsor: Mie University
- || Lucentis (ranibizumab) / Roche, Novartis
New P2/3 trial: RaTAPDR: 25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China (clinicaltrials.gov) - Jan 2, 2015
P2/3, N=120, Not yet recruiting, Sponsor: JUNYAN ZHANG
- ||| Eylea (aflibercept intravitreal) / Bayer, Regeneron
Observational data: TITAN: Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD (clinicaltrials.gov) - Dec 22, 2014
P=N/A, N=200, Not yet recruiting, Sponsor: Bayer
- ||||| Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD. (clinicaltrials.gov) - Dec 22, 2014
P4, N=100, Recruiting, Sponsor: Nagoya City University
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis, Macugen (pegaptanib) / Bausch Health
New P4 trial: Cohort Study of the Clinical Course of Macular Diseases in Kagawa (clinicaltrials.gov) - Dec 22, 2014
P4, N=1000, Not yet recruiting, Sponsor: Kagawa University
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Enrollment change, Trial primary completion date: Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=16, Completed, Sponsor: Vitreo-Retinal Associates, Michigan
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Jun 2015 Recruiting --> Completed | N=40 --> 16 | Trial primary completion date: Jan 2014 --> Apr 2014
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: OCTAVE: Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Dec 17, 2014
P3, N=671, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=40 --> 16 | Trial primary completion date: Jan 2014 --> Apr 2014 Recruiting --> Active, not recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Trial withdrawal: SURFING: Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids (clinicaltrials.gov) - Dec 12, 2014
P2, N=0, Withdrawn, Sponsor: University of Utah
Recruiting --> Active, not recruiting Terminated --> Withdrawn
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: CONSTELLATION: Efficacy and Safety of Lucentis (clinicaltrials.gov) - Dec 10, 2014
P3, N=155, Recruiting, Sponsor: Novartis Pharmaceuticals
Terminated --> Withdrawn Trial primary completion date: Feb 2017 --> Jan 2018
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Trial primary completion date: OLIMPIC: A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. (clinicaltrials.gov) - Dec 10, 2014
P3, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Feb 2017 --> Jan 2018 N=150 --> 200 | Trial primary completion date: Dec 2015 --> Jun 2016